Mutations in CCAAT/enhancer binding protein α (CEBPA) are seen in 5% to 14% of acute
myeloid leukemia (AML) and have been associated with a favorable clinical outcome. Most …

We evaluated concurrent gene mutations, clinical outcome, and gene expression signatures
of CCAAT/enhancer binding protein alpha (CEBPA) double mutations (CEBPA dm) versus …

Mutations in CCAAT/enhancer binding protein α (CEBPA) occur in 5–10% of cases of acute
myeloid leukemia. CEBPA-double-mutated cases usually bear biallelic N-and C-terminal …

Mutations of CCAAT/enhancer–binding protein alpha (CEBPA mu) are found in 10% to 15%
of de novo acute myeloid leukemia (AML) cases. Double-mutated CEBPA (CEBPA dm) is …

Purpose The transcription factor CCAAT/enhancer binding protein-α (CEBPA) is crucial for
normal myeloid differentiation. Mutations in the CEBPA gene are found in subsets of patients …

Biallelic mutations of the CEBPA gene (CEBPA bi) define a distinct entity associated with
favorable prognosis; however, the role of monoallelic mutations (CEBPA sm) is poorly …

The prognostic impact of mutations in the CCAAT/enhancer binding protein α (CEBPA) gene
was evaluated in the context of concomitant molecular mutations and cytogenetic …

Purpose To evaluate the prognostic significance of CEBPA mutations in the context of
established molecular markers in cytogenetically normal (CN) acute myeloid leukemia …

Mutations of the CCAAT/enhancer binding protein alpha (CEBPA) gene have been
associated with a favorable outcome in patients with acute myeloid leukemia (AML), but …

The CCAAT/enhancer binding protein a is an essential transcription factor for granulocytic
differentiation. Recent studies reported N-and C-terminal CEBPA mutations in approximately …